Introduction: Conservative active surveillance has been proposed for low-risk papillary thyroid microcarcinoma (PTMC), defined as 1.0 cm and lacking clinical aggressive features, but controversy exists with accepting it as not all such PTMCs are uniformly destined for benign prognosis. This study investigated whether BRAF V600E status could further risk stratify PTMC, particularly low-risk PTMC, and can thus help with more accurate case selection for conservative management.
Introduction
Papillary thyroid cancer (PTC) is a common endocrine malignancy with a rapidly rising incidence globally in recent decades [1e4] . Papillary thyroid microcarcinoma (PTMC), defined as tumour 1.0 cm in its greatest dimension [5] , constitutes a major portion of thyroid cancer, close to 50% of all thyroid malignancies in some studies [1, 6, 7] . The Surveillance, Epidemiology, and End Results (SEER) data have shown an increase in the incidence of PTMC from 3.39 per 100,000 person-years in 1983e1985 to 13.02 per 100,000 person-years in 2010e2013, with an average annual percent change of 9.3% [1] . Although the majority of patients with PTMC have an indolent disease course with no serious clinical outcomes, some patients do have tumour metastasis and even disease-specific mortality [8e10] . Of particular note is that recurrence of PTMC can occur after treatment, which may be associated with increased risk of patient morbidity and mortality. Thus, prevention of disease recurrence of PTMC is a major goal of its treatment in the current clinical practice.
It is often difficult to precisely risk stratify and accordingly treat PTMC to achieve an optimal benefitharm balance of the treatments. Therefore, the management style of PTMC, particularly low-risk PTMC, is currently widely variable in different clinical practices around the world, ranging from total thyroidectomy for every patient with PTMC to non-surgical active surveillance in patients with clinically low-risk PTMC. The conservative active surveillance is attractive but controversial as an approach to clinically low-risk PTMC, defined as lack of extrathyroidal extension (ETE), lymph node metastasis (LNM) and distant metastasis (DM), which are well known to be associated with an increased risk of recurrence [9e11]. One major issue is that in some patients initially apparently low-risk PTMC is actually inherently destined, perhaps genetically driven, for a later course of poor prognosisddisease recurrence and even mortality. To identify those patients with PTMC that has clinically apparently low-risk at the initial presentation but has inherently high potential for poor prognosis, such as disease recurrence, is clinically challenging. The opposite is also truedi.e., it may not be always straightforward to identify the cases with apparently low-risk PTMC that is truly of low risk. A novel approach, such as the use of genetic guidance, which could further risk stratify clinically apparently low-risk PTMC, could be useful in helping more precisely to define the management of this common type of thyroid cancer.
In recent years, BRAF V600E mutation has been introduced as a genetic prognostic marker to assist the risk evaluation of PTC [12, 13] . There have also been some studies on PTMC in this regard, but they have been virtually all focused on the overall analyses of PTMC with inconsistent results [11, 14, 17] . There are limited data on the prognostic value of BRAF V600E in the unique category of PTCdclinically low-risk PTMC. More than ten years ago, Mazzaferri suggested that BRAF V600E could be useful in further risk stratification of low-risk PTMC [18] , but current clinical guidelines on the treatment of thyroid cancer, such as the American Thyroid Association guidelines, have not been able to specifically define yet BRAF V600E as a risk-differentiating factor for low-risk PTMC [19] . This controversy derives largely from the fact that direct data on the prognostic value of BRAF V600E in the risk assessment of low-risk PTMC is lacking. There has been particularly lack of a large multicenter study that could provide a strong analysis power to resolve this controversy. In view of this, we conducted the present large international multicenter study to directly investigate the prognostic value of BRAF V600E mutation in PTMC, with a particular emphasis on low-risk PTMC.
Materials and methods

Patients and mutational analyses
This study initially included 2638 patients with PTC from 11 medical centres in six countries, as detailed previously [20e24] . After exclusion of patients with tumour size >1.0 cm, we had 743 patients with PTMC (584 women and 159 men), with a median age of 49 years (interquartile range [IQR], 39e59 years) and a median clinical follow-up time of 53 months (IQR, 25e93 months) from 1978 to 2015. The clinicopathological demographic characteristics of the patients with PTMC in this cohort from different medical centres are presented in Supplemental Table S1 . We defined lowrisk PTMC as having no ETE, LNM, and DM and high-risk PTMC as having at least one of these high-risk characteristics. All patients received total or near-total thyroidectomy. Neck lymph node dissection and radioiodine ablation were pursued when clinically indicated as previously described [16, 22, 23] . Tumour recurrence was defined as combined persistent and recurrent disease confirmed by histologic/cytologic/radiographic/ biochemical criteria as previously described [16] . Follow-up time was defined as the time from initial thyroidectomy to tumour recurrence or to the latest clinical contact in the case of no recurrence. The study was approved by the institutional review board of all the centres involved and informed consent was obtained from patients where required. For BRAF V600E mutation analyses, we amplified exon 15 of the BRAF gene containing the mutation hotspot using polymerase chain reaction primers, as described previously [24e35]. Genetic analyses were performed after surgical and radioiodine ablation treatments in all patients and the BRAF mutation status did not affect the treatment strategy.
Statistical analysis
We presented continuous data as medians and IQRs using the WilcoxoneManneWhitney test for the analysis of non-normally distributed variables and presented categorical data as frequencies and percentage using a chi-squared test for the analysis or Fisher's exact test for small case numbers. KaplaneMeier survival curves with log-rank test were used to analyse the recurrence-free survival. Independent risk factors associated with disease recurrence were examined by Cox-regression analyses to generate hazard ratio (HR) and 95% confidence interval (CI). All reported P values were two-sided and a value <0.05 was considered significant. All analyses were performed using SPSS version 20.0 (IBM SPSS, Inc. New York, NY) and GraphPad Prism version 7 (GraphPad Software, San Diego, CA).
Results
Effect of BRAF V600E mutation on disease recurrence of PTMC in the overall cohort
We first took the advantage of this large multicenter cohort of 743 patients with PTMC to examine the general effect of BRAF V600E mutation on tumour behaviours, particularly disease recurrence, in the overall PTMC cohort ( Table 1 ). The overall prevalence of BRAF V600E mutation in PTMC was 32.4% (241/ 743). BRAF V600E was associated with several high-risk tumour behaviours, such as ETE and LNM. The tumor recurrence rate in patients with BRAF mutationnegative PTMC was significantly lower compared with that of BRAF mutation-positive patients (6.4% versus 10.8%, respectively), with an unadjusted HR of 2.01 (95% CI, 1.20e3.38), which remained significant at 2.44 (95% CI, 1.15e5.20) after adjustment for patient age, sex, conventional pathological risk factors, medical centre, and radioactive iodine treatment ( Table 2) . A significant association between BRAF V600E mutation and decreased recurrence-free survival is also revealed on KaplaneMeier analysis (log-rank P Z 0.007; Fig. 1A ).
Similar results were obtained when the analyses were performed only on a conventional variant of PTMC (CPTMC). The prevalence of BRAF mutation in this group was 32.9% (198/602). Tumour recurrence rates in CPTMC were 6.2% (25/404) versus 12.1% (24/198) in BRAF mutation-negative and BRAF mutation-positive patients, respectively, with an HR of 2.94 (95% CI, 1.20e7.20) after adjustment for patient age, sex, conventional pathological risk factors, medical centre, and radioactive iodine treatment ( Table 2) . On KaplaneMeier analysis, the recurrence-free survival curve of BRAF mutation-positive patients significantly decreased compared with that of BRAF mutationnegative patients (log-rank P Z 0.003; Fig. 1B ).
Effect of BRAF V600E mutation on disease recurrence of low-and high-risk PTMCs
We next examined the effect of BRAF V600E mutation on disease recurrence of PTMC in different risk groups. As shown in Table 3 , the overall BRAF V600E rate was 26.6% (139/522) and disease recurrence rate was 2.1% (11/522) in low-risk PTMC. The recurrence rates were 1.3% versus 4.3% in BRAF mutation-negative versus BRAF mutation-positive patients, respectively, with a HR of 6.65 (95% CI, 1.80e24.65) after adjustment for patient age, sex, medical centre, and radioactive iodine treatment. The negative predictive value of BRAF mutation for recurrence of low-risk PTMC was 98.7% (95% CI, 96.8%e99.5%) ( Table 3 ). In the high-risk group, however, BRAF mutation had no significant effect on tumour recurrence, with a HR of 1.28 (95% CI, 0.69e2.37) after adjustment for patient age, sex, medical centre, and radioactive iodine treatment. On KaplaneMeier analysis, BRAF mutation was associated with a significant decrease in recurrence-free survival curve in low-risk PTMC (log-rank P Z 0.023; Fig. 2A ), whereas in the high-risk group, BRAF mutation had no significant effect on the recurrence-free survival curve (log-rank P Z 0.688; Fig. 2B ).
Similar results were obtained in CPTMC. The recurrence rate in low-risk CPTMC was 1.3% versus 4.3% in BRAF mutation-negative versus BRAF mutation-positive patients, with a HR of 5.15 (95% CI, 1.21 to 21.83) after adjustment for patients age, sex, medical centre, and radioactive iodine treatment (Table 3 ). In high-risk CPTMC, BRAF mutation had no effect on tumour recurrence, with an adjusted HR of 1.34 (95% CI, 0.71 to 2.56). On KaplaneMeier analyses, BRAF mutation was associated with a significant decline in the recurrence-free survival curve in low-risk CPTMC (logrank P Z 0.036; Fig. 2C ), but not in high-risk CPTMC (log-rank P Z 0.422; Fig. 2D ).
Discussion
It can be a challenging task to precisely risk stratify patients with PTMC for prognostic risk level-based [36, 37] , some patients experience tumour recurrence and even mortality [9, 10] , suggesting that all PTMCs do not have the same intrinsic risk for poor outcomes. There are currently ongoing debates particularly on how to further risk stratify and appropriately manage clinically apparently low-risk PTMC.
Controversies exist particularly on how to select cases of such low-risk PTMC for conservative active surveillance.
In this context, the present large international multicenter study has demonstrated that BRAF V600E mutation can be a prognostic marker for poorer clinicopathological outcomes of PTMC, particularly for disease recurrence of low-risk PTMC. In fact, this study has for the first time shown that BRAF mutation can further differentiate the recurrence risk of clinically lowrisk PTMCdwild-type BRAF patients have an extremely low risk of recurrence whereas BRAF mutation patients have a significantly increased recurrence risk, representing an independent prognostic value of BRAF mutation in the apparently clinically low-risk PTMC. Unlike in low-risk PTMC, in high-risk PTMC, BRAF V600E mutation was not an independent risk factor for disease recurrence in the present study. This finding may be expected, given the fact that even in the absence of BRAF mutation, classical high-risk tumour features already existed in high-risk PTMC as defined in the present study, which would be associated with a high recurrence rate. These findings in the present study by analysing low-and high-risk PTMCs separately may now reconcile the inconsistent results of previous studies on the prognostic value of BRAF V600E in the overall analyses of all PTMCs as the outcomes of those studies would vary depending on the compositae portions of low-and high-risk PTMCs in the cohorts of patients included [11,14e17] .
Active surveillance has been recently proposed as an alternative option to surgical treatment in low-risk PTMC, which is drawing increasing attention [19, 38, 39] . It is of concern, however, that all low-risk PTMCs may not uniformly remain "silent" without clinical consequences [40e42]. It is also unknown what molecular markers can distinguish intrinsically aggressive but initially apparently low-risk PTMC from truly indolent low-risk PTMC. A striking finding in the present study was the extremely low recurrence rate in lowrisk PTMC that harboured the wild-type BRAF, representing a robust negative predictive value (99%) of BRAF V600E for disease recurrence. It has been recently recommended by Miyauchi and Ito that active surveillance is the primary approach to the management of clinically low-risk PTMC as opposed to immediate surgical treatment [43] . Our present study suggests that this conservative approach is reasonable for BRAF mutation-negative low-risk PTMC given its extremely low recurrence rate. This is supported also by the fact that virtually no PTC-related mortality occurred in patients with BRAF mutation-negative PTC, particularly in patients with conventional PTC, including even PTC >1.0 cm [44] . In this context, because the cost of BRAF test is generally low and the cost of thyroidectomy is high, this BRAF status-based approach to the management of PTMC would spare many patients from total thyroidectomy or even any thyroidectomy and would thus likely be cost-saving, in addition to other advantages.
Our present study demonstrated that BRAF V600E mutation could independently define a significantly increased risk of disease recurrence in initially apparently low-risk PTMC. This finding, together with the well-known other adverse effects of BRAF V600E on PTC [12, 13, 16, 24] , suggests that non-surgical long-term surveillance may not be appropriate for patients with BRAF mutation-positive low-risk PTMC. Even a recurrence rate of 4.3% in the BRAF mutation-positive low-risk PTMC found in the present study seems to be relatively low; this significant increase in recurrence risk compared with BRAF mutation-negative PTMC suggests a significantly increased aggressive potential of the tumour associated with BRAF V600E. This is a concern particularly given that the long-term impact of BRAF mutation on clinical outcomes of thyroid cancer will likely be substantial if significant tumour growth, ETE, or LNM occurs. This is because previous findings suggest that BRAF V600E-positive intrathyroidal PTC >1.0 cm has a substantially increased recurrence risk, particularly in the case of tumours >2.0 cm where there was a robustly increased recurrence risk to around 20e30%, which was comparable with the recurrence risk of invasive PTC [21] . It has been previously demonstrated that BRAF V600E and ETE or LNM has a robustly synergistic adverse effect on clinical outcomes of PTC, including disease recurrence [16] and patient mortality [24] . New ETE and LNM can develop even in initially low-risk PTMC if given sufficient time and even in the absence of significant growth of the primary tumour. Once ETE and LNM occur in BRAF V600Epositive tumour, synergistic interactive effects between the newly developed aggressive pathological factors and BRAF V600E on poor clinical outcomes of PTMC may PTMC, papillary thyroid microcarcinoma; CI, confidential interval. a Adjusted for patient age at diagnosis, sex, medical centres, and radioactive iodine treatments. intensify [16, 24] . Moreover, the adverse effects of BRAF V600E on clinical outcomes of PTC, such as diseasespecific mortality, start to be significantly manifested particularly after 10 years of clinical follow-up from the initial treatment [24] . Therefore, BRAF mutationpositive low-risk PTMC has an aggressive potential if left untreated, making uncertain the feasibility of the long-term non-surgical conservative surveillance for such BRAF mutation-positive thyroid cancer. It is worth noting that BRAF mutation was found only in 26.6% of patients with clinically low-risk PTMC in the present study. Thus, if the BRAF mutation status is used to assist the management of low-risk PTMC, the vast majority of patients could be managed with conservative surveillance although only a minority of patients need to pursue thyroidectomy. It has been recently recommended that a clinical risk level-based approach in the prognostic use of BRAF mutation to the management of PTC be applied and, as such, thyroid lobectomy may be just adequate for BRAF mutation-positive low-risk PTMC [45] .
A limitation of the present study was the relatively small number of patients in the high-risk group of PTMC, reducing the power to conclude the results. Previous studies demonstrated that even though BRAF mutation-negative PTC could have recurrence [16, 46] , PTC-related mortality virtually only occurred in patients with BRAF mutation-positive PTC [44] . Thus, the BRAF mutation status may also have a prognostic value even in high-risk PTMC: absence of the mutation implies virtually no PTMC-related mortality. The lack of information on other mutations, such as rat sarcoma (RAS) mutations and telomerase reverse transcriptase (TERT) promoter mutation, is another limitation of this study. However, RAS mutations are mutually exclusive with BRAF V600E [47] and they alone do not have adverse effects on the outcomes of low-risk PTC [45] . TERT promoter mutation is uncommon in PTMC, which alone is also not associated with aggressiveness of PTMC [48] . We analysed the Johns Hopkins cases, which had information on both the BRAF and TERT mutations, and found that TERT promoter mutation alone indeed had no effect, whereas BRAF mutation alone had a significant effect on disease recurrence either in the overall analysis of all PTMCs or low-risk PTMC; in fact, a remarkable recurrence rate of 13.5% (5/37) was observed in the group with BRAF mutation alone versus only 1.6% (3/189) in the group with no mutation ( Supplemental Table S2 ). BRAF V600E and TERT promoter mutations often coexist in PTC to form an oncogenic genetic duet that is associated with a robustly increased risk of poor clinical outcomes of PTC [44, 46] . The number of cases with this genetic duet was too small in PTMC, particularly low-risk PTMC, to analyse in the present study ( Supplemental Table S2 ).
In summary, in this large multicenter study, we demonstrate that BRAF V600E can further differentiate the prognostic risk of low-risk PTMC: the mutation has an extremely robust negative predictive value for disease recurrence and is associated with a significantly increased recurrence. These results, together with the known aggressive role of BRAF V600E in PTC in general, suggest that BRAF mutation-positive PTMC can be reasonably treated surgically; the feasibility of longterm conservative surveillance of BRAF mutationpositive PTMC initially presenting with low-risk clinical features seems uncertain, making it reasonable at this time to treat such thyroid cancer surgically, albeit with limited surgical extentdthyroid lobectomy, for example. In contrast, conservative management in the form of non-surgical active surveillance is reasonable for BRAF mutation-negative low-risk PTMC, which accounts for the majority of patients with clinically lowrisk PTMC. Thus, more precise management of patients with low-risk PTMC can be achieved by including the BRAF V600E mutation status in the prognostic risk stratification.
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